Sudeep Pharma Limited Updates CIN and Company Status Following Stock Exchange Listing

Sudeep Pharma Limited has completed the formal update of its Corporate Identification Number (CIN) and company status on the Ministry of Corporate Affairs (MCA) website following its stock exchange listing. The pharmaceutical company informed the exchanges about this administrative update through a regulatory filing dated January 16, 2026. CIN Update Details The company's application to the Registrar of Companies, Gujarat, for updating its master data has been processed successfully. The changes reflect the company's transition from an unlisted to a listed entity following its debut on the stock exchanges. Parameter: Previous Status Updated Status CIN: U24231GJ1989PLC013141 L24231GJ1989PLC013141 Company Status: Unlisted Listed Stock Exchange Status: No Yes Company Profile and Listing Information Sudeep Pharma Limited successfully listed on both BSE and NSE on November 28, 2025. The company, incorporated on December 21, 1989, operates in the pharmaceutical sector and is registered under the ROC Ahmedabad jurisdiction. Corporate Details: Information Registration Number: 013141 Date of Incorporation: December 21, 1989 Registered Address: 129/1/A, G.I.D.C. Estate Nandesari, Baroda, Gujarat ROC Jurisdiction: ROC Ahmedabad Company Category: Public, Non-government company Financial and Compliance Status The updated MCA master data reveals key financial parameters and compliance status of the company. Sudeep Pharma maintains active compliance status and operates as a public limited company. Financial Parameters: Amount/Details Authorized Capital: ₹15.00 crores Paid-up Capital: ₹11.29 crores Last AGM Date: August 28, 2025 Balance Sheet Date: March 31, 2025 Compliance Status: Active Compliant Administrative Update Process The CIN update process was initiated following the company's listing on the stock exchanges. Company Secretary and Compliance Officer Dimple Mehta signed the intimation letter digitally, confirming the completion of the administrative formalities. The updated master data from the MCA website has been submitted to both BSE and NSE for their records. The change in CIN prefix from 'U' to 'L' is a standard procedure that indicates the company's listed status, providing transparency to stakeholders and regulatory authorities about the company's current market position. Sudeep Pharma Limited has completed its Q2FY26 results presentation and earnings call, subsequently submitting the audio recording to stock exchanges in compliance with regulatory requirements. The pharmaceutical company conducted its earnings discussion on December 22, 2025, as previously scheduled. Earnings Call Completion The company successfully held its Q2FY26 earnings call on Monday, December 22, 2025, at 11:30 a.m. to discuss operational and financial performance for the quarter and half-year ended September 30, 2025. Following the completion of the call, Sudeep Pharma has now submitted the audio recording to both NSE and BSE as required under Regulation 30 of the SEBI (LODR) Regulations, 2015. Call Details: Information Date Held: December 22, 2025 Time: 11:30 a.m. Purpose: Q2FY26 Results Discussion Period Covered: Quarter and half-year ended September 30, 2025 Audio Recording Accessibility The audio recording of the earnings call has been uploaded to the company's official website and is accessible to all stakeholders. The company has provided direct access to ensure transparency in investor communications. Recording Access: Details Website: https://www.sudeeppharma.com/ Direct Link: https://www.sudeeppharma.com/wp-content/uploads/2025/12/10038645.mp3 Format: MP3 Audio File Transcript Status: To be submitted separately Regulatory Compliance Sudeep Pharma's submission dated December 22, 2025, references its earlier communications dated December 15, 2025, and December 21, 2025, regarding the earnings call intimation and investor presentation respectively. The company has maintained consistent compliance with SEBI listing regulations throughout the process. Company Information The pharmaceutical company operates from its registered office at 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, with its corporate office located at 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat. Corporate Details: Information CIN: U24231GJ1989PLC013141 NSE Symbol: SUDEEPPHRM BSE Scrip Code: 544619 Website: www.sudeepgroup.com The submission was authorized by Dimple Mehta, Company Secretary and Compliance Officer (M.No.: F13184), demonstrating the company's adherence to corporate governance standards and regulatory requirements. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.